Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
agricultural and biological sciences
Evidence for high prevalence of Pneumocystis jirovecii exposure among Cameroonians
Acta Tropica, Volume 112, No. 2, Year 2009
Notification
URL copied to clipboard!
Description
Cameroon lacks the capacity for routine Pneumocystis pneumonia (PcP) diagnosis, thus, the prevalence of Cameroonian exposure to this microbe is unknown. It is known that Pneumocystis infecting different mammalian host species represent diverse phylogenetic backgrounds and are now designated as separate species. The highly sensitive nature of ELISA and the specificity afforded by using human-derived P. jirovecii Msg peptides has been shown to be useful for serological analysis of human sera. Thus, sera from patients in Yaoundé, the capital city of Cameroon, were analyzed for anti-P. jirovecii antibodies by enzyme-linked immunosorbent assay (ELISA) using three recombinant major surface glycoprotein (Msg) peptide fragments, MsgA1, MsgB, and MsgC1. Based on serum recognition of one or more of the three fragments, 82% of the total samples analyzed was positive for antibodies to P. jirovecii Msg, indicating high prevalence of P. jirovecii infection or colonization among Cameroonians. Different Msg fragments appear to be recognized more frequently by sera from different geographic regions of the globe. Antibodies in the Cameroonian serum samples recognized MsgA1 > MsgC1 > MsgB, suggesting that different P. jirovecii strains exist in different parts of the world and/or human populations differ in their response to P. jirovecii. Also, HIV+ patients diagnosed with respiratory infections (such as TB and pneumonia) and maintained on trimethoprim/sulfamethoxazol prophylaxis had relatively lower anti-Msg titers. Whether PcP prophylaxis has significant effects on the quality of life among HIV+ patients in Cameroon warrants further investigation. © 2009 Elsevier B.V.
Authors & Co-Authors
Nkinin, Stephenson W.
United States, Cincinnati
University of Cincinnati
Daly, Kieran R.
United States, Cincinnati
University of Cincinnati College of Medicine
United States
Va Medical Center
Walzer, Peter D.
United States, Cincinnati
University of Cincinnati College of Medicine
United States
Va Medical Center
Ndzi, Edward Shafe
Cameroon, Yaounde
Institute of Medical Research and Medicinal Plant Studies Yaounde
Cameroon, Yaounde
Université de Yaoundé I
Asonganyi, Tazoacha
Cameroon, Yaounde
Université de Yaoundé I
Respaldiza, Nieves
Spain, Sevilla
Hospital Universitario Virgen Del Rocío
Medrano, F. J.
Spain, Sevilla
Hospital Universitario Virgen Del Rocío
Kaneshiro, Edna S.
United States, Cincinnati
University of Cincinnati
Statistics
Citations: 19
Authors: 8
Affiliations: 6
Identifiers
Doi:
10.1016/j.actatropica.2009.07.030
ISSN:
0001706X
Research Areas
Disability
Infectious Diseases
Study Design
Cross Sectional Study
Study Locations
Cameroon